Findings Point to Potential New Use of an Existing Drug
Scientists at The Scripps Research Institute (TSRI) have identified a set of compounds that may be used to treat multiple sclerosis (MS) in a new way. Unlike existing MS therapies that suppress the immune system, the compounds boost a population of progenitor cells that can in turn repair MS-damaged nerve fibers.
One of the newly identified compounds, a Parkinson’s disease drug called benztropine, was highly effective in treating a standard model of MS in mice, both alone and in combination with existing MS therapies.
“We’re excited about these results, and are now considering how to design an initial clinical trial,” said Luke L. Lairson, an assistant professor of chemistry at TSRI and a senior author of the study, which is reported online in Nature on October 9, 2013.
Lairson cautioned that benztropine is a drug with dose-related adverse side effects, and has yet to be proven effective at a safe dose in human MS patients. “People shouldn’t start using it off-label for MS,” he said.
A New Approach
An autoimmune disease of the brain and spinal cord, MS currently affects more than half a million people in North America and Europe, and more than two million worldwide. Its precise triggers are unknown, but certain infections and a lack of vitamin D are thought to be risk factors. The disease is much more common among those of Northern European heritage, and occurs about twice as often in women as in men.
In MS, immune cells known as T cells infiltrate the upper spinal cord and brain, causing inflammation and ultimately the loss of an insulating coating called myelin on some nerve fibers. As nerve fibers lose this myelin coating, they lose their ability to transmit signals efficiently, and in time may begin to degenerate. The resulting symptoms, which commonly occur in a stop-start, “relapsing-remitting” pattern, may include limb weakness, numbness and tingling, fatigue, vision problems, slurred speech, memory difficulties and depression, among other problems.
Current therapies, such as interferon beta, aim to suppress the immune attack that de-myelinates nerve fibers. But they are only partially effective and are apt to have significant adverse side effects.
Scientists at The Scripps Research Institute (TSRI) have identified a set of compounds that may be used to treat multiple sclerosis (MS) in a new way. Unlike existing MS therapies that suppress the immune system, the compounds boost a population of progenitor cells that can in turn repair MS-damaged nerve fibers.
One of the newly identified compounds, a Parkinson’s disease drug called benztropine, was highly effective in treating a standard model of MS in mice, both alone and in combination with existing MS therapies.
“We’re excited about these results, and are now considering how to design an initial clinical trial,” said Luke L. Lairson, an assistant professor of chemistry at TSRI and a senior author of the study, which is reported online in Nature on October 9, 2013.
Lairson cautioned that benztropine is a drug with dose-related adverse side effects, and has yet to be proven effective at a safe dose in human MS patients. “People shouldn’t start using it off-label for MS,” he said.
A New Approach
An autoimmune disease of the brain and spinal cord, MS currently affects more than half a million people in North America and Europe, and more than two million worldwide. Its precise triggers are unknown, but certain infections and a lack of vitamin D are thought to be risk factors. The disease is much more common among those of Northern European heritage, and occurs about twice as often in women as in men.
In MS, immune cells known as T cells infiltrate the upper spinal cord and brain, causing inflammation and ultimately the loss of an insulating coating called myelin on some nerve fibers. As nerve fibers lose this myelin coating, they lose their ability to transmit signals efficiently, and in time may begin to degenerate. The resulting symptoms, which commonly occur in a stop-start, “relapsing-remitting” pattern, may include limb weakness, numbness and tingling, fatigue, vision problems, slurred speech, memory difficulties and depression, among other problems.
Current therapies, such as interferon beta, aim to suppress the immune attack that de-myelinates nerve fibers. But they are only partially effective and are apt to have significant adverse side effects.
Go deeper with Bing News on:
Multiple Sclerosis
- How Multiple Sclerosis Differs In Men And Women
Multiple sclerosis (MS) is a chronic condition that affects the Central Nervous System (CNS). It occurs when the immune system attacks the brain and spinal cord, leading to a mild or a 'worsening' ...
- Progression Independent of Relapse Activity in Multiple Sclerosis
Disability progression independent of relapse activity (PIRA) -- sometimes referred to as silent progression -- is a key integrating concept in the contemporary view of multiple sclerosis (MS)."The ...
- New trial at SickKids explores how diabetes drug may help multiple sclerosis patients
More than 97,000 Canadians have multiple sclerosis (MS) and the country is among those with the highest number of cases in the world. Unlike other neurological conditions, MS tends to develop in ...
- Man to run 145 miles through Nebraska for multiple sclerosis
Every year 21 runners participate in a ultra relay event that stretches across America for multiple sclerosis, and one man will be doing his part by running 145 miles through Nebraska.This year, MS ...
- Number of people living with Multiple Sclerosis (MS) in Northern Ireland increases
A new study has discovered the number of people living with multiple sclerosis (MS) in Northern Ireland has increased by nine per cent .
Go deeper with Google Headlines on:
Multiple Sclerosis
[google_news title=”” keyword=”Multiple Sclerosis” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
MS
- South MS school district is violating transgender student’s civil rights, complaint says
The school district is violating Title IX, a federal civil rights law that prohibits sex discrimination in schools, through its dress code and harassment of transgender students, the American Civil ...
- Iconic MS Coast restaurant named one of the 50 most beautiful in US by People Magazine
Celebrities eat there all the time and the owner is probably going to tell a corny joke or two while you enjoy your meal. Have you ever been?
- Ms. Lauryn Hill Teams Up with Her Son YG Marley for Performance on Fallon: Watch
Factor," "Survival," and "Praise Jah in the Moonlight." Ms. Lauryn Hill Teams Up with Her Son YG Marley for Performance on Fallon: Watch Jo Vito ...
- MS governor signs bill requiring people at public schools to use facilities corresponding to gender assigned at birth
A new law in Mississippi requires individuals to use restrooms and housing at public education institutions that correspond to their gender assigned at birth.
- 'MS is BS' fundraiser in Elkton generates $4K for the cause
Tracey Colbert was glum and withdrawn for quite a while after she had been diagnosed with multiple sclerosis in 2015. But then, after thinking long and hard about ...
Go deeper with Google Headlines on:
MS
[google_news title=”” keyword=”MS” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]